• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.

作者信息

Galtier Jean, Alric Camille, Bérard Emilie, Leguay Thibaut, Tavitian Suzanne, Bidet Audrey, Delabesse Eric, Rieu Jean Baptiste, Vial Jean-Philippe, Vergez François, Lechevalier Nicolas, Luquet Isabelle, Klein Emilie, de Grande Anne-Charlotte, Sarry Audrey, Pigneux Arnaud, Récher Christian, Bertoli Sarah, Dumas Pierre-Yves

机构信息

CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, F-33000, Bordeaux, France.

Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.

出版信息

Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y.

DOI:10.1038/s41408-021-00551-y
PMID:34775463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8590686/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c199/8590686/f343b06ed08d/41408_2021_551_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c199/8590686/f343b06ed08d/41408_2021_551_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c199/8590686/f343b06ed08d/41408_2021_551_Fig1_HTML.jpg

相似文献

1
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.中剂量阿糖胞苷或标准剂量阿糖胞苷加单剂量蒽环类药物作为老年急性髓系白血病患者缓解后治疗：对医疗资源消耗和结局的影响
Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y.
2
Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines.急性髓系白血病巩固治疗策略的比较：单纯大剂量阿糖胞苷与中剂量阿糖胞苷联合蒽环类药物的对比
Ann Hematol. 2015 Sep;94(9):1485-92. doi: 10.1007/s00277-015-2389-9. Epub 2015 May 6.
3
[Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].[蒽环类药物连用3天及阿糖胞苷连用7天的诱导化疗方案治疗老年急性髓系白血病的疗效与安全性]
Gan To Kagaku Ryoho. 2007 Oct;34(10):1617-21.
4
Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.小剂量阿糖胞苷联合阿克拉霉素治疗不适合标准剂量阿糖胞苷联合蒽环类药物治疗的初治急性髓系白血病或高危骨髓增生异常综合征患者。
Anticancer Res. 2012 Apr;32(4):1347-53.
5
Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.与中/大剂量阿糖胞苷及标准剂量阿糖胞苷诱导方案相比，大剂量阿糖胞苷与阿柔比星联合G-CSF方案治疗未缓解急性髓系白血病的疗效
Indian J Cancer. 2019 Apr-Jun;56(2):167-172. doi: 10.4103/ijc.IJC_392_18.
6
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.中剂量阿糖胞苷联合米托蒽醌与标准剂量阿糖胞苷联合柔红霉素治疗老年急性髓系白血病的比较。
Ann Oncol. 2018 Apr 1;29(4):973-978. doi: 10.1093/annonc/mdy030.
7
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?克拉屈滨在成人急性髓系白血病诱导缓解中的应用：我们处于什么位置？
Ann Hematol. 2019 Mar;98(3):561-579. doi: 10.1007/s00277-018-3562-8. Epub 2018 Nov 23.
8
Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.不同剂量阿糖胞苷诱导核心结合因子急性髓系白血病的临床异质性。
Sci Rep. 2020 Jan 20;10(1):685. doi: 10.1038/s41598-020-57414-y.
9
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.硼替佐米联合柔红霉素和阿糖胞苷用于诱导治疗，并在初治 60-75 岁急性髓系白血病患者中联合中剂量阿糖胞苷用于巩固治疗：CALGB（Alliance）研究 10502。
J Clin Oncol. 2013 Mar 1;31(7):923-9. doi: 10.1200/JCO.2012.45.2177. Epub 2012 Nov 5.
10
A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.一种预测新诊断急性髓系白血病患者接受蒽环类药物联合阿糖胞苷诱导化疗期间死亡风险的评分系统。
Cancer. 2012 Jan 15;118(2):410-7. doi: 10.1002/cncr.26273. Epub 2011 Jun 29.

引用本文的文献

1
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.小剂量巩固治疗或中等剂量阿糖胞苷用于60岁以上急性髓系白血病患者缓解后治疗。一项来自DATAML和SAL登记处的回顾性研究。
Am J Hematol. 2025 Jan;100(1):23-32. doi: 10.1002/ajh.27510. Epub 2024 Nov 18.
2
Cost comparison of post-remission strategies in younger and older AML patients in France.法国年轻与老年急性髓系白血病患者缓解后策略的成本比较。
Blood Cancer J. 2023 Jun 28;13(1):100. doi: 10.1038/s41408-023-00874-y.

本文引用的文献

1
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.口服阿扎胞苷维持治疗急性髓系白血病缓解后。
N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444.
2
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.60 岁及以上初诊完全缓解的急性髓系白血病成人患者的缓解后治疗：治疗强度对结局的影响。
Ann Hematol. 2020 Apr;99(4):773-780. doi: 10.1007/s00277-020-03922-w. Epub 2020 Feb 22.
3
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.
对于无不良细胞遗传学特征的老年急性髓系白血病患者，在传统化疗基础上加用洛莫司汀可提高生存率：LAM-SA 2007 FILO试验结果
J Clin Oncol. 2018 Nov 10;36(32):3203-3210. doi: 10.1200/JCO.2018.78.7366. Epub 2018 Sep 27.
4
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
5
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
6
Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.65-70 岁初发急性髓系白血病患者缓解后治疗的影响：两个伴有重叠年龄纳入标准的同时随机 ALFA 试验的比较。
Haematologica. 2011 Jun;96(6):837-44. doi: 10.3324/haematol.2010.036921. Epub 2011 Apr 1.
7
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.50 至 70 岁急性髓系白血病患者强化蒽环类药物诱导和重组白细胞介素-2 维持治疗的随机研究：ALFA-9801 研究结果。
J Clin Oncol. 2010 Feb 10;28(5):808-14. doi: 10.1200/JCO.2009.23.2652. Epub 2010 Jan 4.
8
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.老年急性髓系白血病患者在强化诱导化疗后首次完全缓解期的缓解后治疗：多中心随机急性白血病法国协会（ALFA）9803试验结果
Blood. 2007 Jun 15;109(12):5129-35. doi: 10.1182/blood-2007-02-069666. Epub 2007 Mar 6.
9
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.老年初发急性髓系白血病患者缓解后治疗：一项比较米托蒽醌与中剂量阿糖胞苷及标准剂量阿糖胞苷的随机试验
Blood. 2001 Aug 1;98(3):548-53. doi: 10.1182/blood.v98.3.548.
10
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.成人急性髓系白血病缓解后强化化疗。癌症与白血病B组。
N Engl J Med. 1994 Oct 6;331(14):896-903. doi: 10.1056/NEJM199410063311402.